Siddharth, S.; Kuppusamy, P.; Wu, Q.; Nagalingam, A.; Saxena, N.K.; Sharma, D.
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2022, 23, 8083.
https://doi.org/10.3390/ijms23158083
AMA Style
Siddharth S, Kuppusamy P, Wu Q, Nagalingam A, Saxena NK, Sharma D.
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2022; 23(15):8083.
https://doi.org/10.3390/ijms23158083
Chicago/Turabian Style
Siddharth, Sumit, Panjamurthy Kuppusamy, Qitong Wu, Arumugam Nagalingam, Neeraj K. Saxena, and Dipali Sharma.
2022. "Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma" International Journal of Molecular Sciences 23, no. 15: 8083.
https://doi.org/10.3390/ijms23158083
APA Style
Siddharth, S., Kuppusamy, P., Wu, Q., Nagalingam, A., Saxena, N. K., & Sharma, D.
(2022). Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 23(15), 8083.
https://doi.org/10.3390/ijms23158083